Literature DB >> 18637078

Where are people being tested for anti-HCV in England? Results from sentinel laboratory surveillance.

L J Brant1, M Hurrelle, M A Balogun, P Klapper, M E Ramsay.   

Abstract

SUMMARY: Many people infected with hepatitis C virus (HCV) are unaware of their infection and are, therefore. potentially infectious to others. To enable effective case-finding policies to be developed, an understanding of where people, and injecting drug users (IDUs) in particular, are accessing HCV antibody testing is needed. HCV antibody testing data were collected electronically from 21 sentinel laboratories in England between 2002 and 2006 in this cross-sectional study. Service types of the physician requesting the HCV test were identified and classified. Differences in people being tested in each service type and over time were investigated. Over half a million people were tested in 5 years. Whilst most testing took place in hospital, a large proportion of people were tested in community care, particularly in general practice surgeries and genito-urinary medicine clinics. Younger people were more likely to be tested in community care, and there was evidence that testing differed according to ethnic status. IDUs were tested in all parts of the health services, although the highest proportion positive were from prisons and specialist services for drug users. Testing increased between 2002 and 2005 whilst the proportion of people testing positive declined. Routine laboratory data can provide valuable information on where people are being tested for HCV. Risk exposures should be investigated and testing targeted to people at higher risk for infection. Local laboratories should review data on testing locations and proportion positive to inform local initiatives to improve testing and yield.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18637078     DOI: 10.1111/j.1365-2893.2008.01000.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  5 in total

1.  High seroprevalence of HCV in the Abruzzo Region, Italy: results on a large sample from opt-out pre-surgical screening.

Authors:  Ennio Polilli; Monica Tontodonati; Maria Elena Flacco; Tamara Ursini; Palmira Striani; Dante Di Giammartino; Maurizio Paoloni; Luigi Vallarola; Gabriella Lucidi Pressanti; Giorgia Fragassi; Patrizia Accorsi; Lamberto Manzoli; Giustino Parruti
Journal:  Infection       Date:  2015-09-12       Impact factor: 3.553

Review 2.  Are the testing needs of key European populations affected by hepatitis B and hepatitis C being addressed? A scoping review of testing studies in Europe.

Authors:  Jeffrey V Lazarus; Ida Sperle; Alexander Spina; Jürgen K Rockstroh
Journal:  Croat Med J       Date:  2016-10-31       Impact factor: 1.351

3.  Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) - a natural experiment (protocol).

Authors:  Matthew Hickman; John F Dillon; Lawrie Elliott; Daniela De Angelis; Peter Vickerman; Graham Foster; Peter Donnan; Ann Eriksen; Paul Flowers; David Goldberg; William Hollingworth; Samreen Ijaz; David Liddell; Sema Mandal; Natasha Martin; Lewis J Z Beer; Kate Drysdale; Hannah Fraser; Rachel Glass; Lesley Graham; Rory N Gunson; Emma Hamilton; Helen Harris; Magdalena Harris; Ross Harris; Ellen Heinsbroek; Vivian Hope; Jeremy Horwood; Sarah Karen Inglis; Hamish Innes; Athene Lane; Jade Meadows; Andrew McAuley; Chris Metcalfe; Stephanie Migchelsen; Alex Murray; Gareth Myring; Norah E Palmateer; Anne Presanis; Andrew Radley; Mary Ramsay; Pantelis Samartsidis; Ruth Simmons; Katy Sinka; Gabriele Vojt; Zoe Ward; David Whiteley; Alan Yeung; Sharon J Hutchinson
Journal:  BMJ Open       Date:  2019-09-24       Impact factor: 2.692

4.  Hepatitis B and C testing strategies in healthcare and community settings in the EU/EEA: A systematic review.

Authors:  Lauren M K Mason; Irene K Veldhuijzen; Erika Duffell; Ayla van Ahee; Eveline M Bunge; Andrew J Amato-Gauci; Lara Tavoschi
Journal:  J Viral Hepat       Date:  2019-08-16       Impact factor: 3.728

5.  Using surveillance data to determine treatment rates and outcomes for patients with chronic hepatitis C virus infection.

Authors:  Sam Lattimore; Will Irving; Sarah Collins; Celia Penman; Mary Ramsay
Journal:  Hepatology       Date:  2014-02-28       Impact factor: 17.425

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.